Make money doing the work you believe in
CABA Just Got Lilly-Validated. The Thesis Is Working.
Cabaletta Bio prices a $150M raise with Eli Lilly as a strategic participant. The financing overhang is dead. The autoimmune cell therapy M&A clock just started ticking louder.
The Deal
Cabaletta Bio (NASDAQ: CABA) priced a public offering this morning. 51.7 million shares at $2.90, gross proceeds $150 million. Investors of note include Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management, multiple new mutual and sovereign wealth funds, and Eli Lilly and Company.
The stock opened up roughly 11 percent on the news. Pre-deal close was $2.94, currently trading around $3.26.
The Lilly Tell
The headline is not the dollar amount. It is Lilly.
Big pharma does not take small biotech equity stakes lightly. Lilly's BD organization runs a deliberate playbook in cell therapy, and stepping in at the equity round is the classic "look before you leap" move. They get information rights, board-level visibility, and a seat at the table for any future strategic conversation. The data confirms or it does not, and if it does, the buyer is already inside the tent.
The timing is the key. UCB acquired Candid Therapeutics yesterday for up to $2.2 billion. $2 billion upfront, $200 million in milestones. Candid is a two-year-old San Diego biotech with a Phase 1 lead asset and roughly 100 patients dosed across multiple early-stage trials. That is the comp.
T-cell engagers and CAR-T plays in autoimmune just became the hottest M&A vertical in biotech. Lilly buying CABA equity the day after UCB-Candid is not coincidence. It is positioning.
The Going Concern Is Dead
The bear case on CABA had one legitimate complaint, runway. The 10-K filed March 23 carried a going concern flag. Cash was $133.6 million at year-end with a monthly burn around $11 million. Cash-only runway extended into late 2026, early 2027.
Post-raise, total cash sits around $230 million. Forward runway extends roughly 20 months on cash alone, into early 2028. Plus 53 million warrants from the June 2025 offering still sitting as contingent capital if exercised.
The funding overhang is gone. Cantor Fitzgerald reaffirmed Overweight today with a $30 price target, citing exactly this dynamic.
M&A Hunter Dual Scoring
M&A Score: 81, High. Up from approximately 76 pre-raise. The Lilly equity participation is a five-point bump on its own as a strategic tell. The financing overhang removal is another clean lift. Five indications with curative signals across myasthenia gravis, lupus, scleroderma, myositis, and ANCA vasculitis. ASGCT data printing next week. Manufacturing derisked via the Cellares automation deal. Autoimmune CAR-T M&A precedent now anchored at $2.2 billion via UCB-Candid.
Deductions remain. Still pre-Phase 3. The new issuance dilutes existing holders by roughly 47 percent. Warrant overhang from the June 2025 raise is unchanged. No formal LOI yet.
Growth Score: 72, High. Up from 67. Financial Strength jumped from 8 to 12 with the raise. Market Position lifted from 6 to 8 on Lilly validation. Management Execution gets a point for raising at a premium to the last close, that is smart timing not desperation.
Tag: Dual Catalyst. Both scores cleared the threshold. M&A above 80 is a real tier shift.
Frame 2 Buyout Math
10 analysts. Mean price target $13.39, median $13.77, range $2.02 to $31.50. Recs split 6 strong buy, 7 buy, 3 hold, 0 sell. No D. Boral or HC Wainwright in the stack, no haircuts apply.
Median $13.77 with a 1.2 to 1.4x M&A overlay gives a $16.52 to $19.28 takeout zone. With Lilly as the anchor strategic and UCB-Candid as the live comp, a deal could materially exceed median assumptions. UCB paid $2.2 billion for Candid at a similar developmental stage. CABA's post-raise market cap sits in the $360 to $400 million range depending on tape. The math has room to run.
Catalyst Stack
May 11 to 15. ASGCT 2026 in Boston. Rese-cel data without preconditioning chemotherapy, plus automated manufacturing data. The data prints into a Lilly-validated tape.
May 14 to 15. Q1 2026 earnings.
H2 2026. Phase 3 readiness gating. FDA dialogue advances.
BLA target in myositis on the 17-patient single-arm registrational cohort.
2027 to 2028. Realistic M&A timeline window.
Risks Worth Naming
Phase 3 has not started. The conditioning-free thesis still needs ASGCT confirmation. Dilution is real, 47 percent share count expansion overnight. The Lilly equity stake is positioning, not an LOI. The UCB-Candid comp is a comp, not a guarantee. Autoimmune CAR-T is heating up which means competition is heating up too. Sana, Capstan, Kyverna, FATE, all printing data into the same window.
The Trade
CABA at $3.26 with $230 million in the bank, Lilly on the cap table, ASGCT data next week, and a $2.2 billion live M&A comp in the same vertical is a different setup than CABA at $2.94 with going concern flagged. The thesis just got materially derisked on the financial side and validated on the strategic side. The data still has to land, but the runway to land it is no longer in question.
For the M&A Hunter universe, this is the cleanest first-rung autoimmune cell therapy exposure with a named strategic on the cap table. The position-sizing rule per the higher score (81) puts this in the 3 to 5 percent band for new entries. Trim into ASCO-style data rips, hold the core, let the strategic conversation develop on its own clock.
The 2027 to 2028 M&A timeline window I have publicly committed to is now operating with stronger fundamentals underneath it. That is what validation looks like in real time.